Four a-galactosidase gene mutations were identified in Japanese male patients with Fabry disease who had no detectable agalactosidase activity. Two of them were novel mutations, an l l-bp deletion in exon 2 and a g 1 to t substitution at the 3' end of the splice acceptor site in intron l. The former caused a frameshift and led to the creation of a new stop codon at codon 118. The latter was predicted to provoke aberrant mRNA splicing followed by accelerated degradation of the mRNA. A nonsense mutation, R301X, and a 2-bp deletion starting at nucleotide position 718, which were reported previously, were also identified in unrelated patients.
Introduction
Fabry disease is an X-linked recessive disorder caused by a genetic defect of lysosomal a-galactosidase (a-D-galactoside galactohydrolase, EC 3.2.1.22; a-Gal). a-Gal catalyses the hydrolysis of the a-linked galactose residues in the non-reducing terminals of glycosphingolipids (e.g. predominantly globotriaosylceramide). In Fabry disease, deficient a-Gal activity results in the progressive accumulation of natural substrates in various tissues, mainly in lysosomes of the vascular endothelium. The major clinical manifestations in hemizygotes with no detectable a-Gal activity include pain in the distal extremities and acroparesthesia, angiokeratoma, hypohidrosis, corneal opacity in childhood, and progressive vasculopathy of the kidneys, heart, and central nervous system (Desnick et al., 1995) . Recently, atypical hemizygotes with residual a-Gal activity and progressive cardiomyopathy of late onset were reported von Scheidt et al., 1991; Nagao et at., 1991; Nakao et al., 1995) .
The a-Gal gene, which is located at Xq22, is approximately 12-kbp long and consists of 7 exons, ranging from 92-bp to 291-bp in length (Bishop et al., 1988; Kornreich et al., 1990) . These exons are suitable for amplification by means of the polymerase chain reaction (PCR) with intronic oligonucleotide primers. So far, more than 80 a-Gal gene mutations have been identified in patients with Fabry disease Fukuhara et al., 1990; Koide et al., 1990; Yokoi et al., 1991; Ishii et al., 1991 Ishii et al., , 1992 yon Scheidt et al., 1991; Eng et al., 1993 Eng et al., , 1994 Davies et al., 1993 Davies et al., , 1994 Ploos van Amstel et al., 1994; Okumiya et al., 1995a, b) including at least 27 Japanese patients. These mutations were heterogeneous, and about half of them were point mutations causing single amino acid substitutions. In this communication, sequencing analysis was performed with amplified genomic DNA including an exon and small portion of the adjacent intron sequence. Two novel mutations and two reported mutations were identified in Japanese male patients with Fabry disease.
Patients
The patients were unrelated Japanese Fabry hemizygotes, and their clinical manifestations are briefly summarized in Table 1 . All patients had the classical form of the disease, oe-Gal activity being deficient in leukocytes.
Materials and Methods
Cell culture and isolation of genomic DNA and poly(A)+RNA. Lympho- + + + + a-Galactosidase activity a < 1 < 1 < 1 < 1 Enzyme activity in leukocytes was expressed in munits/mg protein; normal control (mean+_ SD), 98.6_+27.3, n=37. NE, not examined. blast lines were established by transformation with Epstain-Barr virus, and cultured at 37~ under 5% CO2 in RPMI-1640 medium (Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal calf serum and antibiotics. Genomic DNA and poly(A)+RNA were isolated from the cultured cells by the standard techniques (Sambrook et al., 1989) .
Amplification and sequencing of genornic DNA. The seven exons that encode the entire a-Gal mRNA and their flanking sequences were amplified by PCR using seven sets of intronic oligonucleotide primers under appropriate PCR conditions for each exon (Takenaka et aL, 1996) . The PCR products were subcloned with a pGEM-T Vector System (Promega, Madison, WI, USA). Nucleotide sequences were determined with a DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). At least two clones were sequenced for each patient, and both forward and reverse strand sequencing reactions were carried out for each clone.
First-strand cDNA synthesis and a-Gal cDNA amplification. The firststrand cDNA was synthesized using First-strand cDNA Synthesis Kit (Amersham, The reaction was carried out in 100/zl of reaction mixture containing 0.5/~g of each PCR primer, and 2.5 units of Taq DNA polymerase (AmpliTaq; Perkin Elmer-Cetus). The conditions for thermal cycling with a DNA Thermal Cycler (Perkin Elmer-Cetus) were; 35 cycles of denaturing for 1 rain at 94~ annealing for 2 rain at 56~ and extension for 3 rain at 72~ The PCR product was subjected to Northern hybridization analysis of a-Gal mRNA. Northern hybridization analysis was performed with poly(A)+RNA as a sample according to the standard method (Sambrook et al., 1989) . Five micrograms of poly(A)+RNA was electrophoretically separated in a formaldehyde-agarose gel, transferred to a nylon membrane (Hybond-N; Amersham), and then hybridized with an entire a-Gal cDNA probe labeled with [a-32P]dCTP. After washing of the filter with 10 mM Tris-HC1 (pH 7.4) at 95~ second hybridization was performed with an [a-32p]-dCTP-labeled fl-actin cDNA probe as a sampling control.
Assaying of a-Gal activity and protein determination, a-Gal activity was
assayed with an artificial substrate, 4-methylumbelliferyl a-D-galactopyranoside (Nacalai Tesque, Kyoto, Japan) as described previously (Mayes et al., 1981) . One unit of enzyme activity was defined as 1.0,umol 4-methylumbelliferone released per hour at 37~ Protein concentrations were determined with a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Results and Discussion
In this communication, we performed gene analysis on four Japanese male patients with Fabry disease, who had been newly diagnosed on the basis of clinical manifestations and leukocyte a-Gal activity, and identified two novel mutations and two reported ones. In Patient l, an ll-bp deletion starting at nucleotide position 317 of cDNA, Del llb (#317-327), was found (Fig. 1) . It resulted in replacement of 106-LQADPQRFPHGIR-118 in the normal sequence by 106- Fig. 3 . Agarose gel electrophoresis of oe-Gal cDNA fragments amplified by PCR. oeGal cDNA fragment comprising exon 1-4 and a part of exon 5 was prepared from a normal control (N) and Patient 2 (P2). Lane M, molecular weight marker. The fragments were stained with ethidium bromide and visualized under ultraviolet light after electrophoresis in 1.5% agarose gel.
PSALSSWDSPASX-118 in the patient. Since an 8-bp direct repeat sequence (5'-AGGCAGAC-3') was observed at the sequence flanking the breakpoint junction, it seems to have been caused by slipped mispairing (Krawczak and Cooper, 1991) during DNA replication. In Patient 2, a g-1 to t substitution at the 3' end of the splice acceptor site in intron 1, Int 1-SA (#195-1g~t), was found (Fig. 2) . On PCRamplification for a-Gal cDNA, trace level of normal size fragment (823 bp) was detected, but other fragment (e.g. truncated fragment resulting from exon skipping) was not observed for the patient under the condition described before (Fig. 3) . Furthermore, Northern hybridization analysis revealed that the amount of a-Gal mRNA had markedly decreased in the patient as compared with that in normal control (Fig. 4) . These findings suggest that Int 1-SA mutation provokes aberrant pre-mRNA splicing, and abnormally processed RNA is subjected to accelerated degradation in cells due to a conformational change of RNA molecule, resulting in marked decrease in the amount of mRNA. Some mutations at the splice acceptor site, which abolished proper RNA splicing, were reported in inherited diseases; fl-thalassemia in which the processed mRNA contained an extended exon (Antonarakis et al., 1984) , Tay-Sachs disease in which an exon skipping occurred (Tanaka et al., 1993) . Three mutations at the splice acceptor site in the a-Gal gene The base number of a-Gal cDNA according to Bishop et al. (1988) .
b Created amino acid sequence at the indicated codon number. ~ Splice acceptor site.
were also reported in Fabry disease; one mutation which was occurred in intron 3 resulted in a complete deletion of exon 4 (Yokoi et aL, 1991) , others were not investigated for RNA processing (Eng et al., 1993; Davies et al., 1994) . In our case, since the amount of a-Gal mRNA markedly decreased in Patient 2, it seems that a-Gal enzyme protein is hardly synthesized in the cells. Two reported mutations were identified in Patients 3 and 4 (Table 2) . Patient 3 had a nonsense mutation, R301X, which was also found in an English patient (Eng et aL, 1994) . Patient 4 had a 2-bp deletion starting at nucleotide position 718 in exon 5, Del 2b (#718-719) (Davies et aL, 1994) .
These findings suggest molecular genetic heterogeneity underlying Fabry disease among different ethnic groups. The accumulation of such data will provide us with significant information for understanding the molecular basis and pathogenesis of Fabry disease.
